Rafarma Pharmaceuticals, Inc. (RAFA) Continues to Build Drug Pipeline

Rafarma Pharmaceuticals is one of Russia’s newest and most promising pharmaceutical companies. A company whose development and growth is being actively encouraged by the government, in a move to lessen Russian dependence upon western pharmaceutical companies for widely used pharmaceuticals, Rafarma is currently specializing in the production of generic antibiotics, but has a growing pipeline of other drugs, including proprietary products already approved.

The company expects significant near-term results with its line of current and researched pharmaceuticals, including the following group of antibiotics.

• Benzalconium Fluoride – Open randomized study of the efficacy and safety of the drug “benzalkonium fluoride, topical solution 1 %” in patients with purulent-infected wounds.
• Benzomet – Open randomized study of the efficacy and safety of the drug “benzomet, vaginal suppositories” in patients with urogenital trichomoniasis.
• Benzolete – Open randomized study of the efficacy and safety of “benzolete, lozenges for resorption – 1 mg” in patients with inflammatory diseases of the mucous membranes of the oral cavity and pharynx.
• Benzoteks – Open randomized study comparative study of the efficacy and safety of the drug “benzoteks, vaginal suppositories with benzalkonium FLUORIDE – 18.9 mg” in patients with bacterial vaginosis.

Below is a list of various Rafarma products, in order of expected sales (USD) by 2014. Rafarma also deals with many drugs for contracted production.

• Pasco ($5,910,186)
• Amoxicillin+clav-k ($5,700,175)
• Azithromycin ($4,782,939)
• Clopidogrel ($4,088,210)
• Betahistine ($3,795,417)
• Glibenclamide+Metformin ($3,463,513)
• Metoprolol ($2,911,183)
• Metformin ($2,865,075)
• Bisoprolol ($2,418,957)
• Levofloxacin ($2,338,084)
• Glycine ($2,274,287)
• Vancomycin ($1,467,387)
• Quetiapine ($1,354,435)
• Cefotaxime ($1,193,041)
• Clarithromycin ($1,015,775)
• Ciprofloxacin ($839,219)
• Ibuprofen ($749,831)
• Glimepiride ($719,375)
• Norfloxacin ($710,766)
• Glibenclamide ($653,162)
• Doxycycline ($548,019)
• Risperidone ($486,959)
• Cefuroxime ($399,884)
• Ofloxacin ($362,786)
• Amoxicillin + sulbactam ($196,700)
• Capreomycin ($192,502)
• Lomefloksatsin ($59,309)

For more information, visit www.rafarma.us

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net